FDA Needs Five Centers, Crawford Says; CBER Centennial Is Emotional Affair
Executive Summary
FDA's five-center structure does not need consolidation beyond the agency's plan to shift biological therapeutic reviews from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research, Acting Commissioner Lester Crawford, PhD, said
You may also be interested in...
CBER-CDER Transition: FDA Creating Template For Product Review Transfer
FDA is creating a template to help it decide what products should be transferred from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research under its proposed reorganization
FDA’s Wait Is Over: Commissioner McClellan Clears Senate
FDA's 21-month wait for a new commissioner is over after Mark McClellan, MD/PhD, was confirmed by the Senate Oct. 17
CBER-CDER Transition: FDA Creating Template For Product Review Transfer
FDA is creating a template to help it decide what products should be transferred from the Center for Biologics Evaluation & Research to the Center for Drug Evaluation & Research under its proposed reorganization